The Wilms’ Tumor (Nephroblastoma) drugs in development market research report provides comprehensive information on the therapeutics under development for Wilms’ Tumor (Nephroblastoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Wilms’ Tumor (Nephroblastoma). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Wilms’ Tumor (Nephroblastoma) and features dormant and discontinued products.
GlobalData tracks 13 drugs in development for Wilms’ Tumor (Nephroblastoma) by 12 companies/universities/institutes. The top development phase for Wilms’ Tumor (Nephroblastoma) is phase ii with six drugs in that stage. The Wilms’ Tumor (Nephroblastoma) pipeline has 11 drugs in development by companies and two by universities/ institutes. Some of the companies in the Wilms’ Tumor (Nephroblastoma) pipeline products market are: Exelixis, Orphelia Pharma and Lantern Pharma.
The key targets in the Wilms’ Tumor (Nephroblastoma) pipeline products market include Receptor Type Tyrosine Protein Kinase FLT3, Proto Oncogene Tyrosine Protein Kinase ROS, and Proto Oncogene Tyrosine Protein Kinase Receptor Ret.
The key mechanisms of action in the Wilms’ Tumor (Nephroblastoma) pipeline product include Proto Oncogene Tyrosine Protein Kinase ROS Inhibitor with two drugs in Phase II. The Wilms’ Tumor (Nephroblastoma) pipeline products include seven routes of administration with the top ROA being Oral and four key molecule types in the Wilms’ Tumor (Nephroblastoma) pipeline products market including Small Molecule, and Cell Therapy.
Wilms’ Tumor (Nephroblastoma) overview
Wilms’ Tumor also known as Nephroblastoma is a type of cancer in one kidney commonly seen in children and is the most common cancer in children around 3-5 years of age and rarely observed in adults. Although the exact cause is idiopathic genetic alterations in WT1, CTNNB1, and WTX, TP53 and MYNC are believed to cause this. Tumor originates from the persistent metanephric tissue or nephrogenic rests and progresses during childhood. It is associated with other congenital syndromes like Beckwith- Wiedemann syndrome, WAGR syndrome, Denys-Drash syndrome. Abnormal abdominal mass, abdominal pain, hematuria, UTI infection, anemia, fever, hyper or hypotension are the common signs and symptoms. Physical examination by pressing carefully on the abdomen, laboratory tests of blood and urine, radiographic findings MRI, CT scan of abdomen. Surgical procedure is nephrectomy (removal of kidney) and systemic chemotherapy with vincristine and dactinomycin, doxorubicin, cyclophosphamide, etoposide, and carboplatin.
For a complete picture of Wilms’ Tumor (Nephroblastoma)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
